omeprazole has been researched along with Gastroparesis in 1 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Gastroparesis: Chronic delayed gastric emptying. Gastroparesis may be caused by motor dysfunction or paralysis of STOMACH muscles or may be associated with other systemic diseases such as DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare pharmacokinetics between immediate and delayed-release omeprazole in patients with GERD associated with gastroparesis." | 9.14 | Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. ( Eversmann, J; Mann, S; Wo, JM, 2010) |
| "To compare pharmacokinetics between immediate and delayed-release omeprazole in patients with GERD associated with gastroparesis." | 5.14 | Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. ( Eversmann, J; Mann, S; Wo, JM, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wo, JM | 1 |
| Eversmann, J | 1 |
| Mann, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis[NCT00492622] | Phase 4 | 12 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The area under the curve for omeprazole concentration-time curve for immediate release and delayed release omeprazole. (NCT00492622)
Timeframe: 0 to 5 hrs after the study drug was ingested on treatment day 7
| Intervention | mg*h/mL (Mean) |
|---|---|
| All Study Participants Immediate Release Arm | 3842 |
| All Study Subjects Delayed Release Arm | 3745 |
Maximal concentration of immediate-release vs. delayed-release omeprazole (NCT00492622)
Timeframe: 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment
| Intervention | ng/mL plasma (Mean) |
|---|---|
| All Study Participants Immediate Release Arm | 1979 |
| All Study Subjects Delayed Release Arm | 1625 |
Time to max concentration for Immediate release vs. Delayed release omeprazole (NCT00492622)
Timeframe: 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 300 min after the study drug was ingested on day 7 of treatment
| Intervention | minutes (Mean) |
|---|---|
| All Study Participants Immediate Release Arm | 32 |
| All Study Subjects Delayed Release Arm | 97 |
1 trial available for omeprazole and Gastroparesis
| Article | Year |
|---|---|
Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis.
Topics: Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Female; Gastri | 2010 |